Research programme: endometriosis therapeutics - Bayer/Evotec SE
Latest Information Update: 28 Jan 2022
At a glance
- Originator Bayer HealthCare; Evotec AG
- Developer Bayer HealthCare; Evotec SE
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Endometriosis